1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. HERON THERAPEUTICS INC

Heron Therapeutics Inc

XNAS: HRTX

Download real time

2.39 0.07 (3.02%)

39.19% Fall from 52W High

2.3M XNAS Volume

XNAS 17 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
24S
5W
2O
2T
364.1

Market Cap

Below industry Median
-26.8

PE TTM

Negative PE TTM
-0.3

PEG TTM

PEG TTM is negative
-10.8

Price to Book

Negative Price to Book
0.2

Beta 1Year

Very Low volatility


Insider Trading disclosures for Heron Therapeutics Inc

The latest disclosure was made by William P. Forbes in Heron Therapeutics Inc where a trade of 187,110 Restricted Stock Units done was reported to US exchanges on Jan. 31, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
William P. Forbes EVP, Chief Development Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 187,110 187,110 - - Restricted Stock Units
William P. Forbes EVP, Chief Development Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 374,220 374,220 - - Employee Stock Option (Right to Buy)
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 1,113,240 1,113,240 - - Employee Stock Option (Right to Buy)
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 556,620 556,620 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 187,110 187,110 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 374,220 374,220 - - Employee Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 83,770 (0%) 0% 0 Common Stock
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 84,130 (0%) 0% 0 Common Stock
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 55,829 (0%) 0% 0 Common Stock
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 87,180 (0%) 0% 0 Common Stock
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 87,180 (0%) 0% 0 Common Stock
Adam Morgan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 17,950 69,777 (0%) 0% 0 Common Stock
Adam Morgan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 83,770 (0%) 0% 0 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 84,130 (0%) 0% 0 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 55,829 (0%) 0% 0 Common Stock
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 87,180 (0%) 0% 0 Common Stock
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 87,180 (0%) 0% 0 Common Stock
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Adam Morgan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 35,900 35,900 - - Stock Option (Right to Buy)
Adam Morgan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 30 Jan 2025 17,950 69,777 (0%) 0% 0 Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 3,874 106,997 (0%) 0% - Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 3,874 46,492 - - Restricted Stock Units
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 13,797 314,867 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 13,797 165,562 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 3,874 120,580 (0%) 0% - Common Stock
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jan 2025 3,874 46,492 - - Restricted Stock Units
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Nov 2024 227,272 227,272 - - Stock Option (Right to Buy)
Michael Kaseta Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Nov 2024 37,879 37,879 (0%) 0% - Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 3,874 50,366 - - Restricted Stock Units
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 3,874 103,123 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 13,797 290,387 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 13,797 179,359 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 3,874 50,366 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Oct 2024 3,874 108,001 (0%) 0% - Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 3,875 99,249 (0%) 0% - Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 3,875 54,240 - - Restricted Stock Units
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 13,797 193,156 - - Restricted Stock Units
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 13,797 276,590 (0%) 0% - Common Stock
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 3,875 104,127 (0%) 0% - Common Stock
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Jul 2024 3,875 54,240 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Jun 2024 12,500 100,252 (0%) 0% - Common Stock
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 16 Jun 2024 12,500 37,500 - - Restricted Stock Units
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Jun 2024 12,500 37,500 - - Restricted Stock Units
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Jun 2024 12,500 95,374 (0%) 0% - Common Stock
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 3,874 58,115 - - Restricted Stock Units
William P. Forbes EVP, Chief Development Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 3,874 82,874 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 13,797 262,793 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 13,797 206,953 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 3,874 88,874 (0%) 0% - Common Stock
Ira Duarte EVP, Chief Financial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.64 per share. 19 Apr 2024 1,122 87,752 (0%) 0% 2.6 2,962 Common Stock
Ira Duarte EVP, Chief Financial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Apr 2024 3,874 58,115 - - Restricted Stock Units
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 03 Apr 2024 62,500 248,996 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 03 Apr 2024 62,500 187,500 - - Restricted Stock Units
Ira Duarte EVP, Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 371,935 371,935 - - Employee Stock Option (Right to Buy)
Dissanaike Sharmila Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 83,685 83,685 - - Stock Option (Right to Buy)
Duarte Ira EVP, Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 61,989 61,989 - - Restricted Stock Units
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 83,685 83,685 - - Stock Option (Right to Buy)
Craig Johnson A. Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 13,948 65,820 (0%) 0% 0 Common Stock
Waage Christian Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 13,948 66,180 (0%) 0% 0 Common Stock
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 41,078 41,078 - - Employee Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 83,685 83,685 - - Stock Option (Right to Buy)
P. Forbes William EVP, Chief Development Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 61,989 61,989 - - Restricted Stock Units
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 83,685 83,685 - - Stock Option (Right to Buy)
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 220,750 220,750 - - Restricted Stock Units
A. Craig Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 1,324,502 1,324,502 - - Employee Stock Option (Right to Buy)
Rodriguez Susan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 13,948 69,230 (0%) 0% 0 Common Stock
Dissanaike Sharmila Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 13,948 69,230 (0%) 0% 0 Common Stock
Morgan Adam Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 83,685 83,685 - - Stock Option (Right to Buy)
Peraza Lisa VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 6,846 6,846 - - Restricted Stock Units
Forbes William P. EVP, Chief Development Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 371,935 371,935 - - Employee Stock Option (Right to Buy)
Adam Morgan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Jan 2024 13,948 51,827 (0%) 0% 0 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2024 1,289 56,663 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2024 552 55,374 (0%) 0% - Common Stock
Peraza Lisa VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2024 1,289 6,675 - - Restricted Stock Units
Peraza Lisa VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.15 per share. 13 Jan 2024 756 55,907 (0%) 0% 2.1 1,625 Common Stock
Peraza Lisa VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2024 552 1,656 - - Restricted Stock Units
Craig A. Collard Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.65 per share. 22 Aug 2023 692 36,496 (0%) 0% 1.7 1,142 Common Stock
Adam Morgan Director Purchase of securities on an exchange or from another person at price $ 0.00 per share. 21 Jul 2023 1,162,891 1,162,891 - - Pre-funded Warrants to Purchase Common Stock
Adam Morgan Director Purchase of securities on an exchange or from another person at price $ 1.37 per share. 21 Jul 2023 2,486,744 6,986,744 (7%) 2% 1.4 3,406,839 Common Stock, par value $0.01 per share
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Jul 2023 150,000 150,000 - - Employee Stock Option (Right to Buy)
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 4,564 35,766 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 4,564 23,372 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 1,250 6,250 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.31 per share. 13 Jul 2023 2,012 33,754 (0%) 0% 1.3 2,636 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 1,250 31,202 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 1,933 26,170 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 1,933 9,896 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 552 2,760 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.31 per share. 13 Jul 2023 860 25,310 (0%) 0% 1.3 1,127 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2023 552 24,237 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.45 per share. 22 May 2023 691 37,188 (0%) 0% 1.5 1,002 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 48,660 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 27,936 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 7,500 - - Restricted Stock Units
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. 13 Apr 2023 2,012 46,648 (0%) 0% 2.9 5,795 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 44,096 (0%) 0% - Common Stock
Kimberly J. Manhard EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 29,747 (0%) 0% - Common Stock
Kimberly J. Manhard EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 27,936 - - Restricted Stock Units
Kimberly J. Manhard EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 7,500 - - Restricted Stock Units
Kimberly J. Manhard EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. 13 Apr 2023 1,417 28,330 (0%) 0% 2.9 4,081 Common Stock
Kimberly J. Manhard EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 25,183 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. 13 Apr 2023 2,012 29,952 (0%) 0% 2.9 5,795 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 27,400 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 31,964 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,250 7,500 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 4,564 27,936 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 552 22,613 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,932 11,829 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 552 3,312 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.88 per share. 13 Apr 2023 860 23,685 (0%) 0% 2.9 2,477 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2023 1,932 24,545 (0%) 0% - Common Stock
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Apr 2023 3,000,000 3,000,000 - - Employee Stock Option (Right to Buy)
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Apr 2023 4,250,000 4,250,000 - - Employee Performance Stock Option (Right to Buy)
Craig A. Collard Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Apr 2023 250,000 250,000 - - Restricted Stock Units
Adam Morgan Director, See Notes 2 & 3 Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Feb 2023 227,272 227,272 - - Stock Option (Right to Buy)
Adam Morgan Director, See Notes 2 & 3 Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Feb 2023 37,879 37,879 (0%) 0% 0 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2023 850,000 850,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2023 66,385 66,385 - - Performance Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2023 149,365 149,365 - - Performance Stock Units
David Szekeres EVP, Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2023 49,788 49,788 - - Performance Stock Units
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Jan 2023 42,631 42,631 - - Performance Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 3,645 167,086 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 16,122 114,807 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 3,645 25,521 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. 13 Jan 2023 5,219 177,989 (0%) 0% 3.2 16,544 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 16,122 183,208 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 3.27 per share. 13 Jan 2023 1,655 163,441 (0%) 0% 3.3 5,416 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 32,500 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 40,294 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. 13 Jan 2023 2,012 42,846 (0%) 0% 3.2 6,378 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 8,750 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 44,858 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 8,750 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 21,381 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 32,500 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 25,945 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Other type of transaction at price $ 3.27 per share. 13 Jan 2023 1,655 20,131 (0%) 0% 3.3 5,416 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. 13 Jan 2023 2,012 23,933 (0%) 0% 3.2 6,378 Common Stock
David Szekeres EVP, Chief Operating Officer Other type of transaction at price $ 3.27 per share. 13 Jan 2023 1,654 22,348 (0%) 0% 3.3 5,413 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 32,500 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 8,750 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. 13 Jan 2023 2,012 26,150 (0%) 0% 3.2 6,378 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 4,564 28,162 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,250 23,598 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,933 13,761 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 552 3,864 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. 13 Jan 2023 1,013 22,061 (0%) 0% 3.2 3,211 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 1,933 23,074 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2023 552 21,141 (0%) 0% - Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 38,580 52,032 (0%) 0% 0 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 77,160 77,160 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 77,160 77,160 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 38,580 51,872 (0%) 0% 0 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 38,580 52,232 (0%) 0% 0 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 77,160 77,160 - - Stock Option (Right to Buy)
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 77,160 77,160 - - Stock Option (Right to Buy)
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 38,580 55,282 (0%) 0% 0 Common Stock
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 77,160 77,160 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Dec 2022 38,580 55,282 (0%) 0% 0 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 16,122 167,005 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 16,122 130,929 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 3,646 29,166 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 13 Oct 2022 5,219 161,786 (0%) 0% 3.8 19,623 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 3,646 150,883 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 10,000 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 36,492 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 41,056 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 13 Oct 2022 2,012 39,044 (0%) 0% 3.8 7,565 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 37,064 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 13 Oct 2022 2,012 18,476 (0%) 0% 3.8 7,565 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 37,064 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 10,000 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 20,488 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 15,924 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 37,064 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 18,142 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 4,564 22,706 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 13 Oct 2022 2,012 20,694 (0%) 0% 3.8 7,565 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,250 10,000 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 553 19,518 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,932 15,694 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 553 4,416 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.76 per share. 13 Oct 2022 861 20,589 (0%) 0% 3.8 3,237 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2022 1,932 21,450 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 165,961 165,961 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 165,961 165,961 - - Employee Stock Option (Right to Buy)
David Szekeres EVP, Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 165,961 165,961 - - Employee Stock Option (Right to Buy)
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jul 2022 60,902 60,902 - - Employee Stock Option (Right to Buy)
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. 13 Jul 2022 5,219 147,237 (0%) 0% 3.0 15,709 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 16,122 147,051 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 3,646 32,812 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 3.84 per share. 13 Jul 2022 1,504 132,688 (0%) 0% 3.8 5,778 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 3,646 136,334 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 16,122 152,456 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 37,254 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 41,628 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 32,690 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 11,250 - - Restricted Stock Units
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. 13 Jul 2022 2,012 35,242 (0%) 0% 3.0 6,056 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 41,628 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 12,122 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 16,686 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. 13 Jul 2022 2,012 14,674 (0%) 0% 3.0 6,056 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 11,250 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Other type of transaction at price $ 3.84 per share. 13 Jul 2022 1,505 13,090 (0%) 0% 3.8 5,782 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 14,340 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 18,904 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. 13 Jul 2022 2,012 16,892 (0%) 0% 3.0 6,056 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,250 11,250 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 4,564 41,628 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.01 per share. 13 Jul 2022 860 18,965 (0%) 0% 3.0 2,589 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 552 4,969 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,933 17,626 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 552 17,892 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2022 1,933 19,825 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Sale of securities on an exchange or to another person at price $ 4.76 per share. 03 May 2022 1,504 10,872 (0%) 0% 4.8 7,154 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Other type of transaction at price $ 3.84 per share. 03 May 2022 1,504 12,376 (0%) 0% 3.8 5,778 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 3,646 120,281 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 16,122 163,173 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 3,646 36,458 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. 13 Apr 2022 5,219 131,184 (0%) 0% 6.1 31,679 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 16,122 136,403 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 33,452 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 46,192 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 12,500 - - Restricted Stock Units
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. 13 Apr 2022 2,012 31,440 (0%) 0% 6.1 12,213 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 28,888 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 12,884 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 12,500 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 46,192 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. 13 Apr 2022 2,012 10,872 (0%) 0% 6.1 12,213 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 8,320 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 13,597 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 4,564 46,192 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 12,500 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. 13 Apr 2022 2,012 11,585 (0%) 0% 6.1 12,213 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,250 9,033 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,932 19,559 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 552 5,521 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.07 per share. 13 Apr 2022 860 17,340 (0%) 0% 6.1 5,220 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 1,932 18,200 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 552 16,268 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 3,646 105,732 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 16,122 179,295 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 3,646 40,104 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 13 Jan 2022 5,219 116,635 (0%) 0% 8.3 43,318 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 16,122 121,854 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 50,756 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 25,086 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 29,650 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 13 Jan 2022 2,012 27,638 (0%) 0% 8.3 16,700 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 13,750 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 9,082 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 13 Jan 2022 2,012 7,070 (0%) 0% 8.3 16,700 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 13,750 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 50,756 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 4,518 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 50,756 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 5,231 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 4,564 9,795 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 13 Jan 2022 2,012 7,783 (0%) 0% 8.3 16,700 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,250 13,750 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,933 16,682 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 1,933 21,491 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 552 6,073 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.30 per share. 13 Jan 2022 966 15,716 (0%) 0% 8.3 8,018 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2022 552 14,749 (0%) 0% - Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 10,452 13,452 (0%) 0% 0 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 20,903 20,903 - - Stock Option (Right to Buy)
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 10,452 16,702 (0%) 0% 0 Common Stock
Susan Rodriguez Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 20,903 20,903 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 20,903 20,903 - - Stock Option (Right to Buy)
Sharmila Dissanaike Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Dec 2021 10,452 16,702 (0%) 0% 0 Common Stock
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2021 20,903 20,903 - - Stock Option (Right to Buy)
Craig A. Johnson Director Sale of securities on an exchange or to another person at price $ 9.73 per share. 21 Dec 2021 250 2,840 (0%) 0% 9.7 2,432 Common Stock
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2021 10,452 13,292 (0%) 0% 0 Common Stock
Christian Waage Director Sale of securities on an exchange or to another person at price $ 9.73 per share. 21 Dec 2021 300 3,200 (0%) 0% 9.7 2,920 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2021 20,903 20,903 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2021 10,452 13,652 (0%) 0% 0 Common Stock
John W. Poyhonen President & CCO Other type of transaction at price $ 9.36 per share. 29 Oct 2021 817 23,836 (0%) 0% 9.4 7,646 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 390,834 390,834 - - Employee Stock Option (Right to Buy)
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 3,646 103,049 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. 13 Oct 2021 963 102,086 (0%) 0% 10.6 10,160 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 3,646 43,750 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 195,417 195,417 - - Restricted Stock Units
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 92,200 92,200 - - Employee Stock Option (Right to Buy)
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 55,320 55,320 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 15,000 - - Restricted Stock Units
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. 13 Oct 2021 433 23,019 (0%) 0% 10.5 4,568 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 23,452 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 3,701 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 55,320 55,320 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 92,200 92,200 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 15,000 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. 13 Oct 2021 433 3,268 (0%) 0% 10.5 4,568 Common Stock
David Szekeres EVP, Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 55,320 55,320 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 4,414 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. 13 Oct 2021 433 3,981 (0%) 0% 10.5 4,568 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 1,250 15,000 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 92,200 92,200 - - Employee Stock Option (Right to Buy)
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 552 14,388 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 23,424 23,424 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2021 13,013 13,013 - - Employee Stock Option (Right to Buy)
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Oct 2021 552 6,625 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.55 per share. 13 Oct 2021 191 14,197 (0%) 0% 10.5 2,015 Common Stock
Craig A. Johnson Director Sale of securities on an exchange or to another person at price $ 12.30 per share. 21 Sep 2021 250 3,090 (0%) 0% 12.3 3,074 Common Stock
Christian Waage Director Sale of securities on an exchange or to another person at price $ 12.31 per share. 21 Sep 2021 300 3,500 (0%) 0% 12.3 3,692 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 3,645 100,366 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. 13 Jul 2021 963 99,403 (0%) 0% 13.5 12,981 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 3,645 47,396 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 13.90 per share. 13 Jul 2021 1,529 96,721 (0%) 0% 13.9 21,249 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 16,250 - - Restricted Stock Units
John W. Poyhonen President & CCO Other type of transaction at price $ 13.90 per share. 13 Jul 2021 971 21,385 (0%) 0% 13.9 13,494 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 22,635 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. 13 Jul 2021 433 22,202 (0%) 0% 13.5 5,837 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 2,884 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 16,250 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. 13 Jul 2021 433 2,451 (0%) 0% 13.5 5,837 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 16,250 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Other type of transaction at price $ 13.90 per share. 13 Jul 2021 1,530 2,347 (0%) 0% 13.9 21,263 Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. 13 Jul 2021 433 3,164 (0%) 0% 13.5 5,837 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 1,250 3,597 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 552 14,027 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Other type of transaction at price $ 13.90 per share. 13 Jul 2021 1,530 13,475 (0%) 0% 13.9 21,263 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jul 2021 552 7,177 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.48 per share. 13 Jul 2021 191 13,836 (0%) 0% 13.5 2,575 Common Stock
Craig A. Johnson Director Sale of securities on an exchange or to another person at price $ 15.20 per share. 21 Jun 2021 250 3,340 (0%) 0% 15.2 3,801 Common Stock
Christian Waage Director Sale of securities on an exchange or to another person at price $ 15.20 per share. 21 Jun 2021 300 3,800 (0%) 0% 15.2 4,559 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Sale of securities on an exchange or to another person at price $ 17.66 per share. 03 May 2021 1,529 1,634 (0%) 0% 17.7 27,009 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Other type of transaction at price $ 13.90 per share. 03 May 2021 1,529 3,163 (0%) 0% 13.9 21,249 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 17,500 - - Restricted Stock Units
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 20,847 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. 13 Apr 2021 433 20,414 (0%) 0% 16.7 7,214 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. 13 Apr 2021 433 1,634 (0%) 0% 16.7 7,214 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 17,500 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 2,067 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. 13 Apr 2021 433 817 (0%) 0% 16.7 7,214 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 17,500 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 1,250 1,250 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 552 12,136 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.66 per share. 13 Apr 2021 191 11,945 (0%) 0% 16.7 3,182 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2021 552 7,729 - - Restricted Stock Units
Craig A. Johnson Director Sale of securities on an exchange or to another person at price $ 17.22 per share. 06 Apr 2021 250 3,590 (0%) 0% 17.2 4,305 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 3,646 92,872 (0%) 0% - Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 3,646 54,687 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. 13 Jan 2021 963 91,909 (0%) 0% 18.2 17,488 Common Stock
John W. Poyhonen President & CCO Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. 13 Jan 2021 433 19,597 (0%) 0% 18.2 7,863 Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 20,030 (0%) 0% - Common Stock
John W. Poyhonen President & CCO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 18,750 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 1,250 (0%) 0% - Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 18,750 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. 13 Jan 2021 433 817 (0%) 0% 18.2 7,863 Common Stock
David Szekeres EVP, Chief Operating Officer Sale of securities on an exchange or to another person at price $ 18.09 per share. 13 Jan 2021 827 0 (0%) 0% 18.1 14,960 Common Stock
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 18,750 - - Restricted Stock Units
David Szekeres EVP, Chief Operating Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 1,250 1,250 (0%) 0% - Common Stock
David Szekeres EVP, Chief Operating Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. 13 Jan 2021 423 827 (0%) 0% 18.2 7,682 Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 552 11,811 (0%) 0% - Common Stock
Lisa Peraza VP, Chief Accounting Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Jan 2021 552 8,281 - - Restricted Stock Units
Lisa Peraza VP, Chief Accounting Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.16 per share. 13 Jan 2021 227 11,584 (0%) 0% 18.2 4,122 Common Stock
David Szekeres EVP, Chief Operating Officer Sale of securities on an exchange or to another person at price $ 19.66 per share. 08 Jan 2021 3,571 0 (0%) 0% 19.7 70,219 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 22 Dec 2020 10,000 10,000 (0%) 0% 13 130,000 Common Stock
Kimberly J. Manhard Director, EVP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 22 Dec 2020 10,000 48,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Director, EVP, Drug Development Sale of securities on an exchange or to another person at price $ 20.00 per share. 22 Dec 2020 10,000 0 (0%) 0% 20 200,000 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 3,000 3,000 (0%) 0% 0 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 18,000 18,000 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 18,000 18,000 - - Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 3,000 3,840 (0%) 0% 0 Common Stock
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 18,000 18,000 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 21 Dec 2020 3,000 4,400 (0%) 0% 0 Common Stock
John W. Poyhonen President & CCO Other type of transaction at price $ 11.65 per share. 30 Oct 2020 637 18,780 (0%) 0% 11.7 7,423 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 350,000 350,000 - - Employee Stock Option (Right to Buy)
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 58,333 58,333 - - Restricted Stock Units
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 12.12 per share. 13 Oct 2020 1,158 89,226 (0%) 0% 12.1 14,036 Common Stock
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 170,000 170,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen President & CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 20,000 20,000 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 20,000 20,000 - - Restricted Stock Units
Kimberly J. Manhard Director, EVP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 120,000 120,000 - - Employee Stock Option (Right to Buy)
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 765 765 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 437 437 - - Stock Option (Right to Buy)
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 103,000 103,000 - - Employee Stock Option (Right to Buy)
Lisa Peraza VP, Chief Accounting Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 13 Oct 2020 8,833 8,833 - - Restricted Stock Units
Kimberly J. Manhard Director, Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 13.97 per share. 01 May 2020 1,158 0 (0%) 0% 14.0 16,176 Common Stock
Kimberly J. Manhard Director, Executive VP, Drug Development Other type of transaction at price $ 12.12 per share. 01 May 2020 1,158 1,158 (0%) 0% 12.1 14,036 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Apr 2020 1,426 1,426 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Apr 2020 713 713 - - Stock Option (Right to Buy)
Barry D. Quart Director, President & CEO Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 6,584 88,068 (0%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 297,714 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 121,500 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 41,189 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 201,000 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 80,400 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 20,402 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 20,402 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 230,000 5,017,203 (5%) 0% 0 Common Stock
Kevin C. Tang Director Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2019 9,000 5,017,203 (5%) 0% 0 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 325,000 325,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen Director, EVP, Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 55,562 55,562 - - Employee Stock Option (Right to Buy)
Kevin C. Tang Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 17,000 17,000 - - Stock Option (right to buy)
Kimberly J. Manhard Director, Executive VP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 120,000 120,000 - - Employee Stock Option (Right to Buy)
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 15,500 15,500 - - Stock Option (Right to Buy)
Robert E. Hoffman CFO & SVP, Finance Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 100,000 100,000 - - Employee Stock Option (Right to Buy)
Craig A. Johnson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 23,000 23,000 - - Stock Option (Right to Buy)
Christian Waage Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Dec 2019 17,000 17,000 - - Stock Option (Right to Buy)
Kimberly J. Manhard Director, Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Nov 2019 24,000 58,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Director, Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 26.00 per share. 29 Nov 2019 24,000 0 (0%) 0% 26 624,000 Common Stock
Kimberly J. Manhard Director, Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 29 Nov 2019 24,000 24,000 (0%) 0% 13 312,000 Common Stock
Kevin C. Tang Director Purchase of securities on an exchange or from another person at price $ 17.50 per share. 04 Oct 2019 285,714 5,799,810 (6%) 0% 17.5 4,999,995 Common Stock
Barry D. Quart Director, Chief Executive Officer Purchase of securities on an exchange or from another person at price $ 17.50 per share. 03 Oct 2019 4,571 94,652 (0%) 0% 17.5 79,993 Common Stock
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 18.43 per share. 03 Oct 2019 806 90,081 (0%) 0% 18.4 14,853 Common Stock
John W. Poyhonen Director, EVP, Chief Commercial Officer Purchase of securities on an exchange or from another person at price $ 17.50 per share. 03 Oct 2019 5,143 18,143 (0%) 0% 17.5 90,003 Common Stock
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2019 750 750 - - Stock Option (Right to Buy)
Stephen R. Davis Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Oct 2019 25,000 25,000 - - Stock Option (Right to Buy)
John W. Poyhonen Director, EVP, Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jul 2019 300,000 300,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen Director Purchase of securities on an exchange or from another person at price $ 17.55 per share. 22 May 2019 3,000 13,000 (0%) 0% 17.6 52,650 Common Stock
Christian Waage Director Purchase of securities on an exchange or from another person at price $ 18.04 per share. 15 May 2019 1,400 1,400 (0%) 0% 18.0 25,262 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Other type of transaction at price $ 18.43 per share. 01 May 2019 1,109 1,109 (0%) 0% 18.4 20,437 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 18.86 per share. 01 May 2019 1,109 0 (0%) 0% 18.9 20,918 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 1,992 5,790,245 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 19,304 5,770,941 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 3,955 5,766,986 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 3,955 5,763,031 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 3,955 5,759,076 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 2,025 5,757,051 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 3,955 5,753,096 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 18,989 5,811,226 (7%) 0% 0 Common Stock
Kevin C. Tang None Gift of securities by or to the insider at price $ 0.00 per share. 31 Dec 2018 18,989 5,792,237 (7%) 0% 0 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 300,000 300,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen None Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 19,500 19,500 - - Stock Option (Right to Buy)
John W. Poyhonen None Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 30,000 30,000 - - Stock Option (Right to Buy)
Kevin C. Tang Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 17,000 17,000 - - Stock Option (right to buy)
Kimberly J. Manhard Executive VP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 100,000 100,000 - - Employee Stock Option (Right to Buy)
Robert E. Hoffman CFO & SVP, Finance Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 71,000 71,000 - - Employee Stock Option (Right to Buy)
Craig A. Johnson None Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 21,000 21,000 - - Stock Option (Right to Buy)
Christian Waage None Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 17,000 17,000 - - Stock Option (Right to Buy)
Robert H. Rosen Director, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Dec 2018 300,000 300,000 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 30.62 per share. 02 Nov 2018 494 0 (0%) 0% 30.6 15,125 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Other type of transaction at price $ 23.60 per share. 02 Nov 2018 494 494 (0%) 0% 23.6 11,656 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 01 Oct 2018 6,000 82,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 32.07 per share. 01 Oct 2018 6,000 0 (0%) 0% 32.1 192,433 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 01 Oct 2018 6,000 6,000 (0%) 0% 13 78,000 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. 14 Sep 2018 19,675 89,275 (0%) 0% 7.2 141,660 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Sep 2018 19,675 710,601 - - Employee Stock Option (Right to Buy)
Kevin C. Tang Director, Ten Percent Owner Sale of securities on an exchange or to another person at price $ 35.75 per share. 12 Sep 2018 2,695,000 5,830,215 (7%) 3% 35.8 96,346,250 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 38.85 per share. 02 Jul 2018 100 0 (0%) 0% 38.9 3,885 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 02 Jul 2018 6,000 6,000 (0%) 0% 13 78,000 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Jul 2018 6,000 88,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 37.51 per share. 02 Jul 2018 5,900 100 (0%) 0% 37.5 221,294 Common Stock
Robert E. Hoffman CFO & SVP, Finance Sale of securities on an exchange or to another person at price $ 38.80 per share. 02 Jul 2018 1,060 1,280 (0%) 0% 38.8 41,123 Common Stock
Robert E. Hoffman CFO & SVP, Finance Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 02 Jul 2018 30,000 100,000 - - Employee Stock Option (Right to Buy)
Robert E. Hoffman CFO & SVP, Finance Other type of transaction at price $ 13.22 per share. 02 Jul 2018 744 1,280 (0%) 0% 13.2 9,834 Common Stock
Robert E. Hoffman CFO & SVP, Finance Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.30 per share. 02 Jul 2018 30,000 31,280 (0%) 0% 15.3 459,000 Common Stock
Robert E. Hoffman CFO & SVP, Finance Sale of securities on an exchange or to another person at price $ 38.15 per share. 02 Jul 2018 28,940 2,340 (0%) 0% 38.2 1,104,107 Common Stock
Robert H. Rosen Director, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. 29 Jun 2018 95,531 98,171 (0%) 0% 7.2 687,823 Common Stock
Robert H. Rosen Director, President Sale of securities on an exchange or to another person at price $ 38.13 per share. 29 Jun 2018 92,131 6,040 (0%) 0% 38.1 3,512,918 Common Stock
Robert H. Rosen Director, President Sale of securities on an exchange or to another person at price $ 38.75 per share. 29 Jun 2018 3,400 2,640 (0%) 0% 38.8 131,765 Common Stock
Robert H. Rosen Director, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. 29 Jun 2018 129,469 132,109 (0%) 0% 7.2 932,177 Common Stock
Robert H. Rosen Director, President Sale of securities on an exchange or to another person at price $ 39.14 per share. 29 Jun 2018 75,661 56,448 (0%) 0% 39.1 2,961,122 Common Stock
Robert H. Rosen Director, President Sale of securities on an exchange or to another person at price $ 40.17 per share. 29 Jun 2018 51,696 4,752 (0%) 0% 40.2 2,076,597 Common Stock
Robert H. Rosen Director, President Sale of securities on an exchange or to another person at price $ 41.39 per share. 29 Jun 2018 2,112 2,640 (0%) 0% 41.4 87,415 Common Stock
Robert H. Rosen Director, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Jun 2018 129,469 695,531 - - Employee Stock Option (Right to Buy)
Robert H. Rosen Director, President Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Jun 2018 95,531 600,000 - - Employee Stock Option (Right to Buy)
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 13.22 per share. 21 Jun 2018 1,607 69,600 (0%) 0% 13.2 21,241 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.05 per share. 21 Jun 2018 50,000 119,600 (0%) 0% 9.1 452,500 Common Stock
Barry D. Quart Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 39.05 per share. 21 Jun 2018 50,000 69,600 (0%) 0% 39.1 1,952,500 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Jun 2018 50,000 250,000 - - Employee Stock Option (Right to Buy)
Kevin C. Tang Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 26.00 per share. 29 Mar 2018 192,308 8,525,215 (13%) 0% 26 5,000,008 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Mar 2018 100,000 730,276 - - Employee Stock Option (Right to Buy)
Barry D. Quart Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 29.75 per share. 19 Mar 2018 100,000 67,993 (0%) 0% 29.8 2,975,000 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. 19 Mar 2018 100,000 167,993 (0%) 0% 7.2 720,000 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 19 Mar 2018 18,000 94,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 19 Mar 2018 18,000 18,000 (0%) 0% 13 234,000 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 30.00 per share. 19 Mar 2018 18,000 0 (0%) 0% 30 540,000 Common Stock
Barry D. Quart Director, Chief Executive Officer Sale of securities on an exchange or to another person at price $ 24.75 per share. 14 Mar 2018 100,000 67,993 (0%) 0% 24.8 2,475,000 Common Stock
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 14 Mar 2018 100,000 830,276 - - Employee Stock Option(Right to Buy)
Barry D. Quart Director, Chief Executive Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.20 per share. 14 Mar 2018 100,000 167,993 (0%) 0% 7.2 720,000 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 10 Jan 2018 7,584 112,416 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Sale of securities on an exchange or to another person at price $ 20.00 per share. 10 Jan 2018 7,584 0 (0%) 0% 20 151,680 Common Stock
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.00 per share. 10 Jan 2018 7,584 7,584 (0%) 0% 13 98,592 Common Stock
Barry D. Quart Director, Chief Executive Officer Other type of transaction at price $ 12.62 per share. 18 Dec 2017 1,684 67,993 (0%) 0% 12.6 21,256 Common Stock
Barry D. Quart Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 310,000 310,000 - - Employee Stock Option (Right to Buy)
John W. Poyhonen None Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 19,500 19,500 - - Stock Option (Right to Buy)
Kevin C. Tang Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 17,000 17,000 - - Stock Option (right to buy)
Kimberly J. Manhard Executive VP, Drug Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 120,000 120,000 - - Employee Stock Option (Right to Buy)
Robert E. Hoffman CFO & SVP, Finance Other type of transaction at price $ 13.05 per share. 18 Dec 2017 536 536 (0%) 0% 13.0 6,993 Common Stock
Robert E. Hoffman CFO & SVP, Finance Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 56,667 56,667 - - Employee Stock Option (Right to Buy)
Craig A. Johnson None Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 21,000 21,000 - - Stock Option (Right to Buy)
Christian Waage None Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 17,000 17,000 - - Stock Option (Right to Buy)
Robert H. Rosen Director, President Grant, award, or other acquisition of securities at price $ 0.00 per share. 18 Dec 2017 310,000 310,000 - - Employee Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 24 Apr 2017 16,292 0 - - Stock Option (Right to Buy)
Kimberly J. Manhard Executive VP, Drug Development Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. 24 Apr 2017 5,250 5,250 (0%) 0% 8.8 46,200 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters